108.92
-4.59 (-4.04%)
| Penutupan Terdahulu | 113.51 |
| Buka | 113.50 |
| Jumlah Dagangan | 345,263 |
| Purata Dagangan (3B) | 1,373,457 |
| Modal Pasaran | 5,311,624,192 |
| Harga / Buku (P/B) | 98.35 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Aug 2026 |
| EPS Cair (TTM) | -3.05 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 113.89% |
| Nisbah Semasa (MRQ) | 6.61 |
| Aliran Tunai Operasi (OCF TTM) | -102.25 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -62.83 M |
| Pulangan Atas Aset (ROA TTM) | -39.04% |
| Pulangan Atas Ekuiti (ROE TTM) | -115.39% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Celcuity Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 3.0 |
| Purata | 1.33 |
|
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 13.21% |
| % Dimiliki oleh Institusi | 81.78% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Baker Bros. Advisors Lp | 31 Mar 2026 | 7,915,792 |
| Avoro Capital Advisors Llc | 31 Mar 2026 | 3,375,000 |
| Perceptive Advisors Llc | 31 Mar 2026 | 3,127,200 |
| Rtw Investments, Lp | 31 Mar 2026 | 3,039,621 |
| Nea Management Company, Llc | 31 Mar 2026 | 2,285,561 |
| Soleus Capital Management, L.P. | 31 Mar 2026 | 1,284,378 |
| Tang Capital Management Llc | 31 Mar 2026 | 1,050,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |